JUNIUS DANIEL M sold $845K of IDXX

JUNIUS DANIEL M sold 1,200 shares of IDEXX LABORATORIES INC /DE (IDXX) at an average of $704.07 ($701.68–$705.78, $0.84M total) across 2 trades on 2026-11-04.

Original reporting
SEC EDGAR · JUNIUS DANIEL M
Published Nov 5, 2026, 10:01 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 5, 2026, 10:06 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$IDXX
Bearish
medium confidence
Mentioned
$IDXX
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$IDXXBearishLow
01

Why it matters

The disclosed sale provides fresh data on insider holdings, but its modest size limits trading impact.

02

Market read

A routine insider sale with modest dollar value; low immediate trading relevance.

03

What to watch

Potential upcoming earnings or product announcements that may offset the negative signal.

Relevance 5/10Novelty 4/10Timing: today

Background

Form 4 filings disclose insider transactions; a director's sale is publicly reported and can influence short‑term sentiment.

Company-level read

Ticker impact

$IDXXBearishMedium confidence
Context

Director Junius Daniel M sold 1,200 shares of IDEXX Laboratories for $844,888, filing a Form 4 on 2026-11-05.

Expected impact

likely slight downward pressure as the market prices the insider sell

Evidence & confidence

A $845k sale by a director is material enough to be noted but the amount is relatively small for a mid‑cap, so any price effect is expected to be limited.

Market effects

Minimal impact on the broader diagnostics sector; insider sales are routine.

No discernible regional effect.

Limited to investors tracking IDEXX insider activity.

Counterpoint

The sale could be unrelated to company fundamentals and merely portfolio rebalancing.

Key entities

  • IDEXX Laboratories Inc.

    Provider of diagnostic and veterinary testing equipment.

  • Junius Daniel M

    Director of IDEXX Laboratories.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$IDXXHighAI 8/10

IDEXX Laboratories Inc (IDXX) (Q3 2026) Earnings Call Highlights: Raised Outlook

IDEXX Laboratories reported Q3 2026 earnings, raising its full-year organic growth outlook to nearly 10% despite challenges. US clinic visits declined 1.8%, and macro pressures impacted puppy/kitten adoptions. CoVet acquisition is expected to dilute EPS by $0.13 in 2026. Global Rapid Assay revenues grew 1% organically. The company attributed growth to innovations, record instrument placements, and higher-quality visits.